ArticleInternational urology and nephrology2026
Quality of life and biochemical changes in patients undergoing kidney replacement therapy among patients with end-stage kidney disease: a cross-sectional study from Brunei Darussalam.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of hemodialysis in end-stage renal disease patients on pulmonary function tests: a meta-analysis of cross-sectional studies.Frontiers in physiology · 2025Pooled it
- Quality of life and biochemical changes in patients undergoing kidney replacement therapy among patients with end-stage kidney disease: a cross-sectional study from Brunei Darussalam.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnd-stage kidney disease (ESKD) requires lifelong kidney replacement therapy (KRT), which significantly influences patients' quality of life (QoL). Primary KRT modalities include hemodialysis (HD), peritoneal dialysis (PD), and kidney transplant (KTX), each with varying impacts on QoL and clinical outcomes. Comparative data regarding these modalities in the local context, is limited.
objectivesThis study aims to evaluate and compare the QoL and biochemical profiles of patients undergoing different KRT modalities in Brunei Darussalam.
methodsA cross-sectional study was conducted in 2024 among 574 patients receiving HD, PD, or KTX across all government dialysis centers in Brunei. QoL was assessed using the validated SF-12 questionnaire, and biochemical parameters were collected from Brunei Darussalam Healthcare Information and Management System (BruHIMS). Sociodemographic and clinical data were used to profile and subgroups analysis.
resultsKTX patients reported the highest QoL scores and most favorable biochemical profiles, reinforcing transplantation as the optimal modality when available. Among dialysis patients, PD was associated with higher physical health scores than HD, suggesting better QoL. KTX patients were generally younger, with higher educational and employment levels. Significant differences in biochemical parameters such as hemoglobin, albumin, creatinine, urea, phosphate, and cholesterol were observed across modalities, indicating modality-specific clinical impacts.
conclusionThe findings suggest that PD may be associated with slightly better QoL outcomes compared to HD. However, these differences were not statistically significant and should be interpreted with caution, particularly given the potential for residual confounding inherent in observational study designs. Future research should focus on examining the long-term QoL trajectories among PD patients and identifying strategies to optimize its clinical benefits in the management of ESKD in Brunei.
Indexed as
Identifiers
40884617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.